Lupin and Boehringer Ingelheim announced a joint strategic alliance for co-marketing linagliptin, a novel Dipeptidylpeptidase-4 (DPP-4) inhibitor in India.
Boehringer Ingelheim, one of the fastest growing multinational pharmaceutical company in India (IMS MAT August 2015) has a strong presence in the DPP-4 Inhibitors market in India which is growing at 27% (IMS MAT August 2015). According to the agreement, Lupin will market and sell linagliptin under a separate brand name Ondero (monotherapy) and Ondero Met (fixed-dose combination with metformin) which will be promoted by Lupin's 400 strong dedicated Diabetes specialty field force. Boehringer Ingelheim will continue to sell its linagliptin under the brand names Trajenta (monotherapy) and TrajentaDuo (fixed-dose combination with metformin) through their existing sales force and network.
Powered by Capital Market - Live News
